Italia markets closed
Dow Jones
33.953,90 -9,94 (-0,03%) Nasdaq
13.241,96 +30,15 (+0,23%) Nikkei 225
32.678,62 +276,21 (+0,85%) EUR/USD
1,0597 -0,0051 (-0,48%) Bitcoin EUR
24.828,21 -265,01 (-1,06%) CMC Crypto 200
562,89 +3,38 (+0,60%)
bluebird bio, Inc. (BLUE)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Al 12:06PM EDT. Mercato aperto.
| Chiusura precedente | 3,0400 |
| Aperto | 3,0200 |
| Denaro | 3,0300 x 1300 |
| Lettera | 3,0400 x 1400 |
| Min-Max giorno | 2,9200 - 3,1000 |
| Intervallo di 52 settimane | 2,7800 - 8,5800 |
| Volume | |
| Media Volume | 4.174.090 |
| Capitalizzazione | 323,533M |
| Beta (5 anni mensile) | 0,93 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8600 |
| Prossima data utili | 06 nov 2023 - 10 nov 2023 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,84 |
GlobeNewswireReal Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLOFLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to provide multiple health plans with access to an innovative, outcomes-based agreement for ZYNTEGLO® (betibeglogene autotem
© 2023 Yahoo. Tutti i diritti riservati.
